HealthyPhase 1NCT01282814

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study

A Phase 1 study testing Venlafaxine Hydrochloride and Effexor® XR in people with Healthy, run by Teva Pharmaceuticals USA at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg capsules (test) versus Effexor® XR (reference) administered as the content of 1 x 150 mg extended-release capsule mixed with applesauce under fasting conditions. Read more about this study

Who is it for?: Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for: Healthy
What is being tested?: Venlafaxine Hydrochloride and Effexor® XR
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 24 participants
Where: 1 siteCanada
Study dates: Feb 2003to Mar 2003
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Members of the community at large.
Subjects will be females and/or males, non-smokers, 18 years of age and older.
Female subjects will be postmenopausal or surgically sterilized.

Who cannot join

Clinically significant illness within 4 weeks of the administration of study medication.
Clinically significant surgery within 4 weeks prior to the administration of the study medication.
Any clinically significant abnormality found during medical screening.
Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
Abnormal laboratory tests judged clinically significant.
Positive urine drug screen at screening.

Show all 38Show fewer

Positive testing for hepatitis B, hepatitis C, or HIV at screening.
ECG abnormalities (clinically significant) or vital sign abnormalities at screening.
Subjects with BMI greater than 30.0.
History of significant alcohol abuse within 6 months of the screening visit or any indication of the regular use of more than 14 units of alcohol per week (1 unit is equal to 150 mL of wine, 360mL of beer, or 45 mL of alcohol 40%).
History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, PCP, crack) within 1 year of the screening visit.
History of allergic reactions to venlafaxine.
History of allergic reactions to heparin.
Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication.
Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
History or presence of any clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
Any history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic exposure.
Positive alcohol breath test at screening.
Subjects who have used tobacco in any form within the 90 days preceding study drug administration.
Any food allergies, intolerance, restriction, or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study.
Subjects who have had a depot injection or implant of any drug 3 months prior to administration of study medication.
Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to administration of the study medication as follows:
less than 300 mL of whole blood within 30 days or
300 mL to 500 mL of whole blood within 45 days or
more than 500 mL of whole blood within 56 days.
Subjects who have consumed food or beverages containing grapefruit within 7 days prior to administration of the study medication.
Subjects with clinically significant presence or history of raised intra-ocular pressure or at the risk of acute narrow angle glaucoma.
Subjects who have dentures or braces.
Intolerance to venipunctures.
Subjects with a clinically significant history of tuberculosis, epilepsy, asthma, diabetes, or psychosis will not be eligible for this study.
Subjects who are unable to understand or unwilling to sign the Informed Consent Form.
Subjects with the known presence of volume-depletion.
Subjects predisposed to bleeding of the skin and mucous membrane (impaired platelet aggregation).
Subjects with clinically significant history of seizures.
Additional exclusion criteria for females only:
Breastfeeding subjects.
Positive urine pregnancy test screen at screening.

Trial locations and contacts

1 site in 1 country.

Canada1 site

Anapharm Inc.
Sainte-Foy, Quebec, G1V 2K8

Other trials in Canada

About this study

Official title: Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as the Content of 1 x 150 mg Extended-Release Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.

Conditions: Healthy
Being tested: Venlafaxine Hydrochloride, Effexor® XR
Keywords: Bioequivalence, Healthy Subjects

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Venlafaxine HydrochlorideDrug
150 mg Extended-Release Capsule
Effexor® XRDrug
Also called Venlafaxine Hydrochloride (generic name)
150 mg Extended-Release Capsule

Study groups in NCT01282814
Study group	Role	What they receive
Investigational Test Product	Experimental	Venlafaxine Hydrochloride 150 mg Extended-Release Capsules. Receives: Drug: Venlafaxine Hydrochloride
Reference Listed Drug	Active comparator	Effexor® XR 150 mg Extended-Release Capsules Receives: Drug: Effexor® XR

What is being measured

The primary outcome is the main question the study is designed to answer.

Cmax of Venlafaxine.
Bioequivalence based on Venlafaxine Cmax (maximum observed concentration of drug substance in plasma).
Measured: Blood samples collected over a 48 hour period.
AUC0-t of Venlafaxine.
Bioequivalence based on Venlafaxine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
Measured: Blood samples collected over a 48 hour period.
AUC0-inf of Venlafaxine.
Bioequivalence based on Venlafaxine AUC0-inf (area under the concentration-time curve from time zero to infinity).
Measured: Blood samples collected over a 48 hour period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Feb 2003Mar 2003

First posted25 Jan 2011 (estimated)
Study startFeb 2003
Primary completionMar 2003
Study completionMar 2003

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for HealthyStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Enrolment: 24 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01282814
Sponsor's protocol ID: 30024
Status last verified: Feb 2011
First submitted: 24 Jan 2011
Last updated: 8 Mar 2011
Results posted: Yes, on ClinicalTrials.gov

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
Trained Athletes, Untrained
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
RecruitingPhase 1
A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Healthy

All Healthy trials

Study at a glance

From the registry record, last updated by the sponsor on 8 Mar 2011. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as the Content of 1 x 150 mg Extended-Release Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.
ClinicalTrials.gov ID: NCT01282814
Acronym / sponsor ID: 30024
Conditions: Healthy
Keywords: Bioequivalence, Healthy Subjects
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 24 participants (actual)
Lead sponsor: Teva Pharmaceuticals USAIndustry (pharma, biotech, devices)
Study start: Feb 2003
Primary completion: Mar 2003 (actual)
Study completion: Mar 2003 (actual)
First posted: 25 Jan 2011 (estimated)
Results: Posted 8 Mar 2011

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Investigational Test Product	Experimental	Drug: Venlafaxine HydrochlorideVenlafaxine Hydrochloride 150 mg Extended-Release Capsules.
Reference Listed Drug	Active comparator	Drug: Effexor® XREffexor® XR 150 mg Extended-Release Capsules

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Members of the community at large.
Subjects will be females and/or males, non-smokers, 18 years of age and older.
Female subjects will be postmenopausal or surgically sterilized.

Key exclusion criteria (38 listed)

Clinically significant illness within 4 weeks of the administration of study medication.
Clinically significant surgery within 4 weeks prior to the administration of the study medication.
Any clinically significant abnormality found during medical screening.
Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
Abnormal laboratory tests judged clinically significant.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Venlafaxine Hydrochloride150 mg Extended-Release Capsule	Drug	Investigational Test Product
Effexor® XRAlso: Venlafaxine Hydrochloride (generic name)150 mg Extended-Release Capsule	Drug	Reference Listed Drug

Primary outcome

Cmax of Venlafaxine.
Time frame: Blood samples collected over a 48 hour period.
Bioequivalence based on Venlafaxine Cmax (maximum observed concentration of drug substance in plasma).
AUC0-t of Venlafaxine.
Time frame: Blood samples collected over a 48 hour period.
Bioequivalence based on Venlafaxine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
AUC0-inf of Venlafaxine.
Time frame: Blood samples collected over a 48 hour period.
Bioequivalence based on Venlafaxine AUC0-inf (area under the concentration-time curve from time zero to infinity).

Results and safety

Results posted to the registry on 8 Mar 2011, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Venlafaxine Hydrochloride (Test) First	12	12
Effexor® XR (Reference) First	12	9

Primary outcome: Cmax of Venlafaxine.

Time frame: Blood samples collected over a 48 hour period.. Mean (Standard Deviation). Unit: ng/mL

Measure	Venlafaxine Hydrochloride (Test) n = 19	Effexor® XR (Reference) n = 19
Value	120.07 (45.48)	103.59 (39.47)

Venlafaxine Hydrochloride (Test) vs Effexor® XR (Reference): Ratio of the T/R geometric mean x 100: 115.85 (90% CI 108.45 to 123.72)

Population analysed: All participants that completed the study had their samples analyzed.

Primary outcome: AUC0-t of Venlafaxine.

Time frame: Blood samples collected over a 48 hour period.. Mean (Standard Deviation). Unit: ng*h/mL

Measure	Venlafaxine Hydrochloride (Test) n = 19	Effexor® XR (Reference) n = 19
Value	1972.77 (1425.56)	1800.03 (1270.77)

Venlafaxine Hydrochloride (Test) vs Effexor® XR (Reference): Ratio of the T/R geometric mean x 100: 109.97 (90% CI 103.68 to 116.63)

Population analysed: All participants that completed the study had their samples analyzed.

Primary outcome: AUC0-inf of Venlafaxine.

Time frame: Blood samples collected over a 48 hour period.. Mean (Standard Deviation). Unit: ng*h/mL

Measure	Venlafaxine Hydrochloride (Test) n = 19	Effexor® XR (Reference) n = 19
Value	2163.77 (1647.47)	2065.50 (1626.52)

Venlafaxine Hydrochloride (Test) vs Effexor® XR (Reference): Ratio of the T/R geometric mean x 100: 106.46 (90% CI 101.45 to 111.71)

Population analysed: All participants that completed the study had their samples analyzed.

Adverse events

Time frame: Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Venlafaxine Hydrochloride (Test) First	0 of 24 (0%)	16 of 24 (66.7%)	Not reported
Effexor® XR (Reference) First	0 of 24 (0%)	9 of 24 (37.5%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 8 Mar 2011.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Healthy

Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
Trained Athletes, Untrained
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
RecruitingPhase 1
A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Healthy

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Benoit Girard, M.D. principal investigator

Anapharm

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Venlafaxine Hydrochloride and Effexor® XR in people with Healthy, run by Teva Pharmaceuticals USA at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Mar 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Mar 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cmax of Venlafaxine. (time frame: Blood samples collected over a 48 hour period.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01282814.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2011.